about
Oral anti-pseudomonal antibiotics for cystic fibrosisAdverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacinQuinolones potentiate cefazolin-induced seizures in DBA/2 miceOral anti-pseudomonal antibiotics for cystic fibrosisMycobacteria and the new quinolonesProtective effects of local administration of ciprofloxacin on the risk of pneumococcal meningitis after cochlear implantationTrovafloxacin-associated leukopenia.Assessment of the effects of combination therapy with ciprofloxacin and fenbufen on the central nervous systems of healthy volunteers by quantitative electroencephalography.Ciprofloxacin-induced psychosis.Ciprofloxacin safety in paediatrics: a systematic review.Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites.Fulminant hepatic failure possibly related to ciprofloxacin.New drugs. Anti-infectivesCiprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.Crystal-induced acute kidney injury due to ciprofloxacin.Acute Ciprofloxacin-Induced Crystal Nephropathy with Granulomatous Interstitial Nephritis.Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures.Association of a Tourette-like syndrome with ofloxacin.Impairment of driving by ciprofloxacin.Moxifloxacin-associated neutropenia in a cirrhotic elderly woman with lower extremity cellulitis.Acute kidney injury due to ciprofloxacin for treatment of acute pyelonephritis.
P2860
Q24202879-0E3F4EAE-CC66-421D-BEEB-2A1F816BE026Q24670225-07AC9CB5-9626-4FF4-A919-3ADA58F61F09Q24680102-ABCDACAD-6A30-4A6B-A0A7-B8C531C3DC33Q26471106-3D7CFC1E-D3CB-40F5-8611-B0D38BA5A3D7Q28342507-268E1300-2F05-41A2-9668-99FD1ADD6892Q30499329-3C9F28EC-A048-4F0E-BF5F-DA86BFEC7249Q31989621-3AC2C723-0155-4993-8342-ADCEC7B92C9DQ33696090-A8C529F0-385A-449E-94AD-D8A8DCABB718Q33976922-D3CB458E-E202-4203-A410-3DF7E83F2687Q35161454-AECB81E9-61DB-486B-94E9-7920EB049B55Q35354313-323409C2-C4A7-4F93-8BDE-E821618886A7Q36137838-0B341370-509D-4AAF-A170-C8165281E6EAQ36894213-981B935F-655F-4E03-B17B-E1BA57F209E1Q39214819-FC769587-7B1A-459D-9814-54C2ED9941F2Q39832593-B680F5E9-12DA-4E6A-8319-7113312C1D99Q41499004-B9A3DBB1-7CEB-4A65-839C-D125D512F164Q42261353-738C6BE6-02DF-4240-9190-1D99F52D7B7EQ42282299-BADAB238-56DA-45DA-9F71-6B0AB1487C03Q42553637-72189716-8496-4AE7-BA12-A4310CBB44F1Q42700143-9F7A7D29-19B2-4221-8F00-EA0583946603Q45018924-15B1B4E3-2572-498B-A6EE-3107487506BAQ53971936-232ECC1E-8846-4502-98BA-AC80CC0B29EA
P2860
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Ciprofloxacin: an overview of adverse experiences.
@en
Ciprofloxacin: an overview of adverse experiences.
@nl
type
label
Ciprofloxacin: an overview of adverse experiences.
@en
Ciprofloxacin: an overview of adverse experiences.
@nl
prefLabel
Ciprofloxacin: an overview of adverse experiences.
@en
Ciprofloxacin: an overview of adverse experiences.
@nl
P356
P1476
Ciprofloxacin: an overview of adverse experiences.
@en
P2093
P304
P356
10.1093/JAC/18.SD.187
P407
P478
18 Suppl D
P577
1986-11-01T00:00:00Z